Research graph
References from Ceftazidime–Avibactam Versus Colistin-Based Regimens for Carbapenem-Resistant Enterobacterales Bloodstream Infections: A Six-Year Retrospective Cohort and 30-Day Mortality Analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
The WHO Bacterial Priority Pathogens List 2024: A prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
10.1016/s1473-3099(25)00118-5 · 2025 · External reference
10.20944/preprints202604.0076.v1
10.20944/preprints202604.0076.v1 · External reference
Detection of New Delhi metallo-β-lactamase (blaNDM) and oxacillinase (blaOXA-48) genes among carbapenem-resistant Enterobacteriaceae (CRE) in Jazan Region, Saudi Arabia
10.1038/s41598-026-49160-4 · 2026 · External reference
Carbapenem- and colistin-resistant Klebsiella pneumoniae co-producing NDM-5 and OXA-48 in a teaching hospital from Tunisia
10.1093/jacamr/dlag043 · 2026 · External reference
10.3389/fcimb.2023.1157010
10.3389/fcimb.2023.1157010 · External reference
Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections
10.1093/cid/ciae403 · 2024 · External reference
Comparison of outcomes of KPC-producing Enterobacterales bloodstream infections treated with ceftazidime-avibactam and other conventional antibiotics: Retrospective single-centre study
10.1128/spectrum.02819-25 · 2026 · External reference
Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: A phase 3 randomised trial (ASSEMBLE)
10.1093/jacamr/dlaf131 · 2025 · External reference
Cefiderocol for the treatment of metallo-β-lactamase-producing Gram-negative bacilli: Lights and shadows from the literature
10.1093/cid/ciac082 · 2022 · External reference
Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae
10.1093/cid/cix783 · 2018 · External reference
10.3390/medicina61071275
10.3390/medicina61071275 · External reference
Attributable risk and time course of colistin-associated acute kidney injury
10.2215/cjn.06980717 · 2018 · External reference
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)†
10.1002/phar.2209 · 2019 · External reference
Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae
10.1186/s12941-017-0191-3 · 2017 · External reference
Clinical characteristics and outcomes of bloodstream infections caused by metallo-β-lactamase-producing Enterobacterales in Argentina: A subanalysis of the EMBARCAR prospective multicentre cohort study
10.1093/ofid/ofag124 · 2026 · External reference
Thirty-day mortality associated with carbapenemase-producing Enterobacterales bloodstream infections at a referral hospital in Peru, 2020–2023
10.1093/ofid/ofaf729 · 2025 · External reference
Epidemiology, treatment and outcomes of bloodstream infections due to MBL-producing Enterobacterales in France: A retrospective study
10.1016/j.ijantimicag.2025.107630 · 2025 · External reference
Clinical features and outcomes of infections caused by metallo-β-lactamase-producing Enterobacterales: A 3-year prospective study from an endemic area
10.1093/cid/ciad725 · 2024 · External reference
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): A prospective, multicentre, cohort study
10.1016/s1473-3099(21)00399-6 · 2022 · External reference
Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: Results from a prospective, multinational case-control-control matched cohorts study (EURECA)
10.1016/j.cmi.2023.11.008 · 2024 · External reference
A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae
10.1016/j.mayocp.2016.06.024 · 2016 · External reference
Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: A 5-year cohort study in intensive care patients
10.1016/j.cmi.2025.02.018 · 2025 · External reference
Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens
10.1186/s13613-025-01580-7 · 2025 · External reference
Risk factors for infection after carbapenem-resistant Acinetobacter baumannii colonization
10.1007/s10096-024-04936-2 · 2024 · External reference
10.3389/fmed.2020.00420
10.3389/fmed.2020.00420 · External reference
The double threat: Bacterial and fungal co-/superinfection in viral pneumonia
10.1080/17476348.2026.2629003 · 2026 · External reference
Bacterial co-infections with SARS-CoV-2
10.1002/iub.2356 · 2020 · External reference
Clinical outcomes of carbapenem therapy in OXA-48-producing Enterobacterales infections: A French multicentre cohort, systematic review, and meta-analysis
10.1080/22221751.2026.2671518 · 2026 · External reference
Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant Enterobacterales bloodstream infection: A systematic review and meta-analysis
10.1128/spectrum.02603-21 · 2022 · External reference
Effectiveness and safety of ceftazidime/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant organism infections: A real-world cohort study
10.1080/20523211.2026.2641111 · 2026 · External reference
Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study
10.1016/j.ijantimicag.2025.107650 · 2026 · External reference
Impact of ceftazidime-avibactam on mortality in bloodstream infections: A cohort study in patients with acute leukaemia
2025 · External reference
Ceftazidime-avibactam alone or in combination with aztreonam versus polymyxins in the management of carbapenem-resistant Klebsiella pneumoniae nosocomial infections (CAPRI study): A retrospective cohort study from South India
10.1007/s15010-023-02094-9 · 2024 · External reference
Comparison of effectiveness between ceftazidime/avibactam and other active therapies for oxacillinase-48-producing carbapenem-resistant Klebsiella pneumoniae bacteraemia in Taiwan
10.1007/s40121-025-01210-6 · 2025 · External reference
10.1186/s12879-026-13151-7
10.1186/s12879-026-13151-7 · External reference
Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteraemia
10.1016/j.ijid.2021.05.079 · 2021 · External reference
Absence of evidence is not evidence of absence
10.1136/bmj.311.7003.485 · 1995 · External reference
10.3389/fmicb.2025.1728843
10.3389/fmicb.2025.1728843 · External reference
10.3390/antibiotics14080783
10.3390/antibiotics14080783 · External reference
10.1186/s12879-026-13570-6
10.1186/s12879-026-13570-6 · External reference
Impact of oxacillinase-48 (OXA-48) and New Delhi metallo-β-lactamase (NDM) co-existence on mortality in critically ill patients with Klebsiella pneumoniae bloodstream infections: A prospective controlled study
10.14744/cpr.2026.83834 · 2026 · External reference
Combined therapeutic option for NDM-producing Serratia marcescens: An in vitro study from clinical samples
10.1016/j.bjid.2024.104481 · 2025 · External reference
10.20944/preprints202504.1221.v1
10.20944/preprints202504.1221.v1 · External reference
10.3390/antibiotics14121238
10.3390/antibiotics14121238 · External reference
Unresolved reference
External reference
Ceftazidime-avibactam and aztreonam combination for carbapenem-resistant Enterobacterales bloodstream infections with presumed metallo-β-lactamase production: A systematic review and meta-analysis
10.1080/14787210.2024.2307912 · 2024 · External reference
10.3390/antibiotics14010004
10.3390/antibiotics14010004 · External reference
Bloodstream infection due to a VIM-metallo-β-lactamase-producing Klebsiella pneumoniae treated with cefiderocol in a preterm newborn
10.1007/s40121-022-00735-4 · 2023 · External reference
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: Review of the evidence
10.1186/s13613-023-01146-5 · 2023 · External reference
Ceftazidime-avibactam plus aztreonam for extensively drug-resistant Gram-negative infections in critically ill patients
10.1016/j.jcrc.2025.155207 · 2025 · External reference
Continuous infusion of aztreonam-avibactam after high loading dose for an infection caused by an OXA-48- and NDM-1-co-producing ST147 Klebsiella pneumoniae
10.1007/s40121-025-01294-0 · 2026 · External reference
Carbapenemase type and mortality in bloodstream infections caused by carbapenemase-producing Enterobacterales: A multicentre retrospective cohort study
10.1007/s15010-025-02584-y · 2025 · External reference
10.1186/s12879-026-12837-2
10.1186/s12879-026-12837-2 · External reference
Bacterial co-infections with SARS-CoV-2
10.1002/iub.2356 · ExternalCitation · doi-reference
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)†
10.1002/phar.2209 · ExternalCitation · doi-reference
Risk factors for infection after carbapenem-resistant Acinetobacter baumannii colonization
10.1007/s10096-024-04936-2 · ExternalCitation · doi-reference
Ceftazidime-avibactam alone or in combination with aztreonam versus polymyxins in the management of carbapenem-resistant Klebsiella pneumoniae nosocomial infections (CAPRI study): A retrospective cohort study from South India
10.1007/s15010-023-02094-9 · ExternalCitation · doi-reference
Carbapenemase type and mortality in bloodstream infections caused by carbapenemase-producing Enterobacterales: A multicentre retrospective cohort study
10.1007/s15010-025-02584-y · ExternalCitation · doi-reference
Bloodstream infection due to a VIM-metallo-β-lactamase-producing Klebsiella pneumoniae treated with cefiderocol in a preterm newborn
10.1007/s40121-022-00735-4 · ExternalCitation · doi-reference
Comparison of effectiveness between ceftazidime/avibactam and other active therapies for oxacillinase-48-producing carbapenem-resistant Klebsiella pneumoniae bacteraemia in Taiwan
10.1007/s40121-025-01210-6 · ExternalCitation · doi-reference
Continuous infusion of aztreonam-avibactam after high loading dose for an infection caused by an OXA-48- and NDM-1-co-producing ST147 Klebsiella pneumoniae
10.1007/s40121-025-01294-0 · ExternalCitation · doi-reference
Combined therapeutic option for NDM-producing Serratia marcescens: An in vitro study from clinical samples
10.1016/j.bjid.2024.104481 · ExternalCitation · doi-reference
Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: Results from a prospective, multinational case-control-control matched cohorts study (EURECA)
10.1016/j.cmi.2023.11.008 · ExternalCitation · doi-reference
Mortality due to carbapenem-resistant Acinetobacter baumannii bacteraemia: A 5-year cohort study in intensive care patients
10.1016/j.cmi.2025.02.018 · ExternalCitation · doi-reference
Epidemiology, treatment and outcomes of bloodstream infections due to MBL-producing Enterobacterales in France: A retrospective study
10.1016/j.ijantimicag.2025.107630 · ExternalCitation · doi-reference
Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study
10.1016/j.ijantimicag.2025.107650 · ExternalCitation · doi-reference
Effectiveness of ceftazidime-avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteraemia
10.1016/j.ijid.2021.05.079 · ExternalCitation · doi-reference
Ceftazidime-avibactam plus aztreonam for extensively drug-resistant Gram-negative infections in critically ill patients
10.1016/j.jcrc.2025.155207 · ExternalCitation · doi-reference
A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae
10.1016/j.mayocp.2016.06.024 · ExternalCitation · doi-reference
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): A prospective, multicentre, cohort study
10.1016/s1473-3099(21)00399-6 · ExternalCitation · doi-reference
The WHO Bacterial Priority Pathogens List 2024: A prioritisation study to guide research, development, and public health strategies against antimicrobial resistance
10.1016/s1473-3099(25)00118-5 · ExternalCitation · doi-reference
Detection of New Delhi metallo-β-lactamase (blaNDM) and oxacillinase (blaOXA-48) genes among carbapenem-resistant Enterobacteriaceae (CRE) in Jazan Region, Saudi Arabia
10.1038/s41598-026-49160-4 · ExternalCitation · doi-reference
Ceftazidime-avibactam and aztreonam combination for carbapenem-resistant Enterobacterales bloodstream infections with presumed metallo-β-lactamase production: A systematic review and meta-analysis
10.1080/14787210.2024.2307912 · ExternalCitation · doi-reference
The double threat: Bacterial and fungal co-/superinfection in viral pneumonia
10.1080/17476348.2026.2629003 · ExternalCitation · doi-reference
Effectiveness and safety of ceftazidime/avibactam versus polymyxin B in liver transplant recipients with carbapenem-resistant organism infections: A real-world cohort study
10.1080/20523211.2026.2641111 · ExternalCitation · doi-reference
Clinical outcomes of carbapenem therapy in OXA-48-producing Enterobacterales infections: A French multicentre cohort, systematic review, and meta-analysis
10.1080/22221751.2026.2671518 · ExternalCitation · doi-reference
Cefiderocol for the treatment of metallo-β-lactamase-producing Gram-negative bacilli: Lights and shadows from the literature
10.1093/cid/ciac082 · ExternalCitation · doi-reference
Clinical features and outcomes of infections caused by metallo-β-lactamase-producing Enterobacterales: A 3-year prospective study from an endemic area
10.1093/cid/ciad725 · ExternalCitation · doi-reference
Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections
10.1093/cid/ciae403 · ExternalCitation · doi-reference
Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae
10.1093/cid/cix783 · ExternalCitation · doi-reference
Aztreonam-avibactam for the treatment of serious infections caused by metallo-β-lactamase-producing Gram-negative pathogens: A phase 3 randomised trial (ASSEMBLE)
10.1093/jacamr/dlaf131 · ExternalCitation · doi-reference
Carbapenem- and colistin-resistant Klebsiella pneumoniae co-producing NDM-5 and OXA-48 in a teaching hospital from Tunisia
10.1093/jacamr/dlag043 · ExternalCitation · doi-reference
Thirty-day mortality associated with carbapenemase-producing Enterobacterales bloodstream infections at a referral hospital in Peru, 2020–2023
10.1093/ofid/ofaf729 · ExternalCitation · doi-reference
Clinical characteristics and outcomes of bloodstream infections caused by metallo-β-lactamase-producing Enterobacterales in Argentina: A subanalysis of the EMBARCAR prospective multicentre cohort study
10.1093/ofid/ofag124 · ExternalCitation · doi-reference
Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant Enterobacterales bloodstream infection: A systematic review and meta-analysis
10.1128/spectrum.02603-21 · ExternalCitation · doi-reference
Comparison of outcomes of KPC-producing Enterobacterales bloodstream infections treated with ceftazidime-avibactam and other conventional antibiotics: Retrospective single-centre study
10.1128/spectrum.02819-25 · ExternalCitation · doi-reference
Absence of evidence is not evidence of absence
10.1136/bmj.311.7003.485 · ExternalCitation · doi-reference
10.1186/s12879-026-12837-2
10.1186/s12879-026-12837-2 · ExternalCitation · doi-reference
10.1186/s12879-026-13151-7
10.1186/s12879-026-13151-7 · ExternalCitation · doi-reference
10.1186/s12879-026-13570-6
10.1186/s12879-026-13570-6 · ExternalCitation · doi-reference
Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae
10.1186/s12941-017-0191-3 · ExternalCitation · doi-reference
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: Review of the evidence
10.1186/s13613-023-01146-5 · ExternalCitation · doi-reference
Outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units and prognostic effect of different antimicrobial regimens
10.1186/s13613-025-01580-7 · ExternalCitation · doi-reference
Impact of oxacillinase-48 (OXA-48) and New Delhi metallo-β-lactamase (NDM) co-existence on mortality in critically ill patients with Klebsiella pneumoniae bloodstream infections: A prospective controlled study
10.14744/cpr.2026.83834 · ExternalCitation · doi-reference
10.20944/preprints202504.1221.v1
10.20944/preprints202504.1221.v1 · ExternalCitation · doi-reference
10.20944/preprints202604.0076.v1
10.20944/preprints202604.0076.v1 · ExternalCitation · doi-reference
Attributable risk and time course of colistin-associated acute kidney injury
10.2215/cjn.06980717 · ExternalCitation · doi-reference
10.3389/fcimb.2023.1157010
10.3389/fcimb.2023.1157010 · ExternalCitation · doi-reference
10.3389/fmed.2020.00420
10.3389/fmed.2020.00420 · ExternalCitation · doi-reference
10.3389/fmicb.2025.1728843
10.3389/fmicb.2025.1728843 · ExternalCitation · doi-reference
10.3390/antibiotics14010004
10.3390/antibiotics14010004 · ExternalCitation · doi-reference
10.3390/antibiotics14080783
10.3390/antibiotics14080783 · ExternalCitation · doi-reference
10.3390/antibiotics14121238
10.3390/antibiotics14121238 · ExternalCitation · doi-reference
10.3390/medicina61071275
10.3390/medicina61071275 · ExternalCitation · doi-reference
